• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 Management

The Final Report from ACTT-1 RCT: Remdesivir Decreases Time to Recovery

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Beigel et al. (NEJM, 2020) describe results from the first stage of the Adaptive Covid-19 Treatment Trial (ACTT-1), evaluating treatment with remdesivir vs placebo

METHODS:

  • Double-blind, randomized, placebo-controlled trial
  • Setting
    • 60 trial sites across the Europe, Asia, and North America
  • Participants
    • Adults hospitalized with COVID-19
    • Evidence of lower respiratory tract infection
  • Interventions
    • Remdesivir
      • 200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days
    • Placebo
  • Primary outcome
    • Time to recovery (discharge or hospitalization for infection-control purposes only)
    • Defined as the first day of recovery, during the 28 days after enrollment
  • Secondary outcome
    • Clinical status at day 15

RESULTS:

  • Remdesivir: 541 patients | Placebo: 521 patients
  • Patients who received remdesivir had a shorter median recovery time
    • Remdesivir: median 10 days (95% CI, 9 to 11)
    • Placebo: median 15 days (95% CI, 13 to 18)
    • Rate ratio for recovery: 1.29 (95% CI, 1.12 to 1.4); P<0.001
  • Patients who received remdesivir were more likely to have clinical improvement at day 15 (adjusted for disease severity)
    • Odds ratio 1.5 (95% CI, 1.2 to 1.9)
  • Benefit “most apparent in patients with a baseline ordinal score of 5 (receiving low-flow oxygen)”
  • Mortality (estimated using Kaplan–Meier estimation analysis)
    • By day 15
      • Remdesivir: 6.7%
      • Placebo: 11.9%
    • By day 29
      • Remdesivir: 11.4%
      • Placebo: 15.2%
    • Hazard ratio 0.73 (95% CI, 0.52 to 1.03)
  • Serious adverse events
    • Remdesivir: 24.6%
    • Placebo: 31.6%

CONCLUSION:

  • For adults with COVID-19 and evidence of lower respiratory tract infection, remdesivir was associated with a shorter time to recovery (by approximately 5 days)
  • While benefit was primarily in patients on low-flow oxygen, the authors caution that this does not necessarily mean there is no benefit in other categories (i.e., no oxygen, high-flow oxygen, mechanical ventilation or ECMO)  
  • The authors also state that

Our data also suggest that treatment with remdesivir may have prevented the progression to more severe respiratory disease, as shown by the lower proportion of serious adverse events due to respiratory failure among patients in the remdesivir group

Learn More – Primary Sources:

Remdesivir for the Treatment of Covid-19 — Final Report

Get COVID-19 Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Management Posts
Next >

Related ObG Topics:

Remdesivir Emergency Authorization: FDA Update and Summary of Preliminary NIH Study Data
ACTT-1 Remdesivir RCT: Preliminary Results Now Published
Remdesivir for COVID-19: RCT Results from 10 Hospitals in China

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site